Human papilloma virus is a sexually transmitted infection. It is known to cause almost all cervical cancers and genital warts. Quadrivalent HPV vaccine became available for prophylaxis of young women in 2006, only recently were recommendations issued for prophylasis of young men. HPV vaccination intended for male youth aged 11 - 21 years has focused attention to the need for better acceptability for HPV vaccination and ways to improve compliance among high risk males, especially those in hard to reach populations. More effective delivery of HPV vaccinations to targeted young male populations requires assessment of barriers to care, which entails understanding the populationâs attitudes, understanding their perception of risk, assessing their knowledge of HPV prevention and transmission to meet the needs of the target population, in this case young American Indian men. HPV prevention strategies include abstinence, barrier protection, limiting sexual partners and, most recently, vaccination. Gardasil, the first HPV vaccine, was developed to prevent cervical cancer, precancerous genital lesions, and genital warts caused by certain strains of the virus. The vaccine covers the HPV variants that cause approximately 75 percent of all cervical. cancers and 90 percent of genital warts  The HPV vaccine was initially licensed for and recommended for routine prophylactic use in young women in the age range, 12 to 26 years, with administration in a series of three injections prior to sexual initiation.
American Indian Male College Students Perception and Knowledge of Human Papillomavirus (HPV): Felicia Schanche Hodge
Last date updated on March, 2021